NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Allotera Therapeutics

Allotera Therapeutics

Private
St. Louis, MissouriHealthcare & Life Scienceshttps://alloteratx.com/

Last Round

Series C

Extension

Jul 8, 2026

Total Funding Raised

$186M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Allotera Therapeutics is a clinical-stage biotechnology company developing allogeneic, off-the-shelf CAR-T cell therapies for cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

allogeneic CAR-Toff-the-shelf CAR-TCAR-T cell therapygene editingCRISPR/Cas9cell therapyhematological malignanciesT-cell acute lymphoblastic leukemiaT-ALLT-cell lymphoblastic lymphomaT-LBLoff-the-shelf therapybiotechclinical-stage biotechnext-gen CAR-T

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Allotera Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Allotera Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Allotera Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionJul 8, 2026
Series CAug 27, 2025

Allotera Therapeutics Investors

Notable investors and investment history

Allotera Therapeutics investors
InvestorRounds
LYZZ CapitalSeries C, Series A
Intermediate Capital GroupSeries C
Fidelity Management & Research CompanySeries C
BioGenerator VenturesSeries A, Series C Extension
Tybourne Capital ManagementSeries C
RiverVest Venture PartnersSeries C, Series A
AbingworthSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 8, 2026

    $35M round with BioGenerator Ventures and LightChain Capital.

  • Aug 27, 2025

    $115M round led by Fidelity Management & Research Company.

Allotera Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Allotera Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Allotera Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSt. Louis, Missouri
Year Founded2018
Last FundingJul 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.